Filtered By:
Cancer: Squamous Cell Carcinoma

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 19645 results found since Jan 2013.

Poly(A)-specific ribonuclease protein promotes the proliferation, invasion and migration of esophageal cancer cells
CONCLUSION: PARN has antiapoptotic effects on EC cells and promotes their proliferation, invasion and migration, which is associated with the development of EC and poor patient prognosis. PARN may become a potential target for the diagnosis, prognosis prediction and treatment of EC.PMID:37664151 | PMC:PMC10473923 | DOI:10.3748/wjg.v29.i31.4783
Source: World Journal of Gastroenterology : WJG - September 4, 2023 Category: Gastroenterology Authors: Fu-Wei Zhang Xiao-Wei Xie Meng-Hua Chen Jian Tong Qun-Qing Chen Jing Feng Feng-Ti Chen Wen-Qi Liu Source Type: research

Acute liver failure following immune checkpoint inhibitors
We report the case of a 64-year-old man admitted to intensive care unit for liver failure secondary to immune-mediated hepatitis. This patient suffered from a progressing laryngeal squamous cell carcinoma. A treatment was started with immune checkpoint inhibitors combining anti PD-L1 plus novel anti-TIGIT or placebo (ATEZOLIZUMAB plus TIRAGOLUMAB or placebo), as part of a clinical trial. The patient then developed immune-mediated hepatitis, proven by liver biopsy. Despite 14 days of corticosteroids at 2 mg/kg the condition of the patient worsened, with the development of liver failure. The patient was admitted to intensive...
Source: Cell Research - September 3, 2023 Category: Cytology Authors: Thomas Renault Lucy Meunier Cl ément Monet Source Type: research

Role of interferon alpha-inducible protein 6 in modulating the proliferation, apoptosis and senescence of oesophageal squamous cell carcinoma cells
In conclusion, IFI6 plays a positive role in the proliferation of ESCC cells both in vitro and in vivo, which could be a novel therapeutic target for treating ESCC.PMID:37661181 | DOI:10.26402/jpp.2023.3.04
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: Y Gao J Dai X P Xu P F Liu R H Shi Source Type: research